Clinical trial · Interventional
Considering alloHCT: Opportunities for Patient Reflection During Decision-Making Via Digital Stories
Feasibility and Preliminary Efficacy of a Digital Story Intervention to Facilitate Decision-Making in Patients With Myeloid Cancers Considering Allogeneic Hematopoietic Cell Transplantation
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a two-arm pilot randomized trial that assesses the feasibility and preliminary efficacy of a digital story and values clarification intervention (Considering alloHCT: Opportunities for Patient Reflection During Decision-Making via Digital Stories \[CHORDS\]) compared to usual care among patients with myeloid cancers considering allogeneic hematopoietic cell transplantation (alloHCT).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Myeloid Malignancy | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CHORDS | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Intervention (CHORDS)
- description
- The CHORDS intervention consists of 1) digital stories created by individuals who previously underwent consultation for alloHCT and 2) explicit values clarification exercises designed to help patients reflect on their emotions and clarify what matters to them, including a) an interactive workbook, and b) best-worst scaling (BWS).
- interventionNames
- Other: CHORDS
- type
- NO_INTERVENTION
- label
- Usual Care
- description
- Patients randomized to the usual care arm will receive standard of care. Patients (and their caregivers when available) randomized to usual care will not participate in CHORDS. Patients and caregivers will complete baseline (T1) and post-alloHCT office visit (T3, T4, T5) assessments.
Primary outcomes (1)
- measure
- Percentage of Participants Retained (Feasibility - Retention Rate)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 21 Years
Show eligibility criteria text
Patients Inclusion criteria: 1. Age \>21 years old 2. Diagnosis of myeloid cancer (e.g. AML, MDS, myelofibrosis, CML, or MDS/MPN) 3. Being considered for alloHCT 4. Able to provide informed consent 5. Able to speak English. The reason for this is because the digital stories have been created in the English language and their multimedia form cannot easily be translated. Exclusion criteria 1) Patients with psychiatric or cognitive conditions which the hematologist believes prohibits informed consent or compliance with study procedures Caregivers Inclusion criteria: 1. Age \>18 years old 2. Selected by the patient when asked if there is a "family member, partner, friend or caregiver with whom you discuss or who can be helpful in health-related matters." 3. Caregiver may be paid/professional or informal caregiver 4. Able to provide informed consent 5. Able to speak English Exclusion Criteria: 1\) None Hematologists Inclusion criteria: 1\) Hematologists of the patients who agree to enroll on the study who are part of WCI. Exclusion criteria 1\) None
References
Publications (0)
Data not yet available